Named Bioactive Compounds · Compound
Flavone A (Flavonoid)
Moderate Evidenceflavonoid
Hermetica Superfood Encyclopedia
Flavone A is a bioactive flavonoid that modulates inflammatory pathways including NF-κB, MAPK, and JNK-STAT signaling cascades. It demonstrates antioxidant activity through electron donation from its hydroxyl groups and inhibits multiple kinases including Akt1 and PI3Kγ.
Flavones are a subclass of flavonoids characterized by a C6-C3-C6 skeleton with two phenyl rings and a heterocyclic pyran ring, synthesized by plants through the phenylpropanoid pathway. Common sources include fruits, vegetables, grains, and herbs, with key compounds like apigenin and luteolin occurring as O- or C-glycosides.
No human clinical trials, randomized controlled trials, or meta-analyses for flavones were identified in the research dossier. Current evidence is limited to in vitro and animal studies examining anti-inflammatory and antioxidant mechanisms.
No clinically studied dosage ranges, standardized forms, or preparation methods have been established for flavones based on human trials. Consult a healthcare provider before starting any new supplement.
Flavone A is a base-structure flavonoid (2-phenylchromen-4-one backbone, MW ~222.24 g/mol) and is not a macronutrient source — it provides negligible calories, protein, fat, fiber, or carbohydrates at physiologically relevant doses. Its significance is entirely as a bioactive polyphenolic compound. Key details: • Core structure: C₁₅H₁₀O₂ (unsubstituted flavone); substituted variants (e.g., apigenin/luteolin-type) carry hydroxyl groups at C-5, C-7, and/or C-4' positions that are critical for both antioxidant electron/hydrogen donation and kinase-binding affinity. • Typical dietary occurrence: Found in low concentrations (roughly 0.5–5 mg per 100 g fresh weight) in celery, parsley, chamomile, and certain citrus peels, often as O- or C-glycoside conjugates (e.g., flavone-7-O-glucuronide). • Bioactive concentration in purified form: Research doses commonly range from 10–100 µM in vitro; animal studies use approximately 10–50 mg/kg body weight orally. • Bioavailability notes: Oral bioavailability of aglycone flavones is generally low (estimated <5–10% in humans) due to extensive Phase I (CYP1A2, CYP3A4-mediated hydroxylation) and Phase II metabolism (glucuronidation via UGT1A1/1A3, sulfation via SULT1A1). C-glycosylated forms require intestinal microbial deglycosylation before absorption, further reducing and delaying systemic availability. Peak plasma concentrations after a single oral dose are typically in the low nanomolar-to-low micromolar range. • Key functional groups: Hydroxyl substituents (when present) donate electrons/hydrogens for radical scavenging (ORAC, DPPH activity); the C2–C3 double bond conjugated with the 4-oxo group enables planarity essential for π-π stacking in kinase ATP-binding pockets (Akt1, MKK4, Fyn, PI3Kγ, p38MAPK, JNK3). • No significant vitamin or mineral content intrinsic to the compound itself. • Lipophilicity: LogP ≈ 2.7–3.2 (aglycone), suggesting moderate membrane permeability but poor aqueous solubility (~0.01–0.05 mg/mL in water at 25 °C); glycosylation increases water solubility but reduces passive transcellular absorption. • Protein binding: Extensively bound to serum albumin (>90%), which serves as a plasma reservoir but limits free-fraction bioactivity. • Interaction with gut microbiome: Unabsorbed flavone reaching the colon undergoes C-ring fission by Clostridium and Eubacterium spp., yielding phenylpropionic acid and phloroglucinol derivatives that may contribute additional bioactivity.
Flavone A suppresses inflammatory responses by blocking NF-κB nuclear translocation and inhibiting MAPK and JNK-STAT pathway activation. The compound directly inhibits kinases including Akt1, MKK4, Fyn, PI3Kγ, and p38MAP through competitive binding at their active sites. Its antioxidant effects occur via electron and hydrogen atom donation from hydroxyl groups on the flavone backbone.
Current evidence for Flavone A is limited to in vitro cell culture studies and animal models, with no human clinical trials available. Laboratory studies have demonstrated kinase inhibition and pathway modulation at micromolar concentrations. Animal studies suggest anti-inflammatory effects, but dosages and bioavailability in humans remain unknown. The preliminary nature of existing research prevents definitive conclusions about therapeutic efficacy in humans.
Safety data for Flavone A supplementation in humans is not established due to lack of clinical studies. Theoretical drug interactions may occur with medications metabolized by cytochrome P450 enzymes or anticoagulant therapies. Pregnancy and breastfeeding safety is unknown and should be avoided. Individuals taking immunosuppressive medications should consult healthcare providers due to potential immune system modulation.
